- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2023
- 123 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Webinar
- February 2023
- 180 Minutes
Global
From €324EUR$340USD£272GBP
In biotechnology, the biologics testing market consists of a range of services for the characterization, safety, efficacy, purity, and stability testing of biologic drugs and therapies. This market addresses the needs of biopharmaceutical companies who are engaged in the development and manufacturing of biologics, which include a vast array of products such as monoclonal antibodies, vaccines, recombinant proteins, cell and gene therapies. Quality control and regulatory compliance play a central role in this market, as biologic products must adhere to stringent standards set by authorities like the FDA and EMA. Tests performed may include sterility testing, bioassay, endotoxin and microbial detection, and cell bank characterization. Biologics testing is a critical component of the product life cycle, starting from early-stage development through to clinical trials and commercial production.
Several companies that offer biologics testing services have established their presence in the market. Prominent entities include Eurofins Scientific, SGS S.A., Charles River Laboratories, BioReliance (part of Merck), WuXi AppTec, PPD, Inc., Pharmaceutical Product Development, LLC (also known as PPD), and Catalent, Inc. These companies provide comprehensive testing services to support the biopharmaceutical industry in ensuring the safety and efficiency of biologic therapeutics. Show Less Read more